Barry J. Hoffer

Active 1969–2025

154
Papers
25,973
Citations
94
h-index
150
i10-index

Citations

Citations per year for Barry J. Hoffer1969: 1 citations1970: 5 citations1971: 47 citations1972: 21 citations1973: 41 citations1974: 66 citations1975: 63 citations1976: 75 citations1977: 79 citations1978: 40 citations1979: 55 citations1980: 96 citations1981: 102 citations1982: 67 citations1983: 81 citations1984: 74 citations1985: 91 citations1986: 65 citations1987: 91 citations1988: 77 citations1989: 84 citations1990: 65 citations1991: 73 citations1992: 74 citations1993: 48 citations1994: 60 citations1995: 128 citations1996: 181 citations1997: 248 citations1998: 220 citations1999: 252 citations2000: 209 citations2001: 186 citations2002: 150 citations2003: 185 citations2004: 174 citations2005: 133 citations2006: 144 citations2007: 129 citations2008: 133 citations2009: 136 citations2010: 143 citations2011: 147 citations2012: 121 citations2013: 157 citations2014: 164 citations2015: 160 citations2016: 147 citations2017: 122 citations2018: 111 citations2019: 390 citations2020: 468 citations2021: 408 citations2022: 340 citations2023: 216 citations2024: 413 citations2025: 208 citations2026: 8 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,725 citing papers, 35.7% of this breakdownChina: 557 citing papers, 7.3% of this breakdownUnited Kingdom: 431 citing papers, 5.7% of this breakdownSweden: 408 citing papers, 5.3% of this breakdownGermany: 357 citing papers, 4.7% of this breakdownCanada: 307 citing papers, 4% of this breakdownFrance: 263 citing papers, 3.4% of this breakdownJapan: 244 citing papers, 3.2% of this breakdownItaly: 210 citing papers, 2.8% of this breakdownAustralia: 164 citing papers, 2.2% of this breakdownSpain: 152 citing papers, 2% of this breakdownTaiwan: 146 citing papers, 1.9% of this breakdown
0%35.7%Other 21.8%

Fields

  • Neuroscience42.7%
  • Medicine31.2%
  • Biochemistry, Genetics and Molecular Biology21.7%
  • Psychology0.9%
  • Agricultural and Biological Sciences0.6%
  • Nursing0.6%
  • Other2.3%

Topics

  • Neuroscience and Neuropharmacology Research6.5%
  • Nerve injury and regeneration6.2%
  • Neurogenesis and neuroplasticity mechanisms4.4%
  • Parkinson's Disease Mechanisms and Treatments4.4%
  • Nuclear Receptors and Signaling3.3%
  • Neuroinflammation and Neurodegeneration Mechanisms3%
  • Other72.2%

Coauthors

All papers

Open in search
  1. Role of chronic neuroinflammation in neuroplasticity and cognitive function: A hypothesis

    Authors: , , , , , , , , , , , , , , , , , , - Alzheimer s & Dementia 2022 cited by 211

  2. Characterization of a mouse strain expressing Cre recombinase from the 3′ untranslated region of the dopamine transporter locus

    Authors: , , , , , , , - genesis 2006 cited by 509

  3. High brain lactate is a hallmark of aging and caused by a shift in the lactate dehydrogenase A/B ratio

    Authors: , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2010 cited by 313

  4. Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons

    Authors: , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2007 cited by 601

  5. Germline mitochondrial DNA mutations aggravate ageing and can impair brain development

    Authors: , , , , , , , , , , - Nature 2013 cited by 277

  6. Dopamine Neuron Agenesis in Nurr1-Deficient Mice

    Authors: , , , , , - Science 1997 cited by 1,103

  7. Inhibition of Drp1 mitochondrial translocation provides neural protection in dopaminergic system in a Parkinson’s disease model induced by MPTP

    Authors: , , , - Scientific Reports 2016 cited by 155

  8. The RhoA-ROCK1/ROCK2 Pathway Exacerbates Inflammatory Signaling in Immortalized and Primary Microglia

    Authors: , , , , , , , , , - Cells 2023 cited by 53

  9. A New Treatment Strategy for Parkinson's Disease through the Gut–Brain Axis

    Authors: , , , , , - Cell Transplantation 2017 cited by 137

  10. Amelioration of Acute Sequelae of Blast Induced Mild Traumatic Brain Injury by N-Acetyl Cysteine: A Double-Blind, Placebo Controlled Study

    Authors: , , , , - PLoS ONE 2013 cited by 206

  11. CCL5 via GPX1 activation protects hippocampal memory function after mild traumatic brain injury

    Authors: , , , , , , , , - Redox Biology 2021 cited by 62

  12. Impaired nigrostriatal function precedes behavioral deficits in a genetic mitochondrial model of Parkinson's disease

    Authors: , , , , , , , , , , - The FASEB Journal 2011 cited by 141

  13. Incretin Mimetics as Rational Candidates for the Treatment of Traumatic Brain Injury

    Authors: , , , , , , , , , , , - ACS Pharmacology & Translational Science 2019 cited by 49

  14. Efficacy of N-Acetyl Cysteine in Traumatic Brain Injury

    Authors: , , , , , , , , - PLoS ONE 2014 cited by 107

  15. Targeted Over-Expression of Glutamate Transporter 1 (GLT-1) Reduces Ischemic Brain Injury in a Rat Model of Stroke

    Authors: , , , , , , , , , - PLoS ONE 2011 cited by 110

  16. Impact of Traumatic Brain Injury on Dopaminergic Transmission

    Authors: , , , , , - Cell Transplantation 2017 cited by 75

  17. CCL5 promotion of bioenergy metabolism is crucial for hippocampal synapse complex and memory formation

    Authors: , , , , , , , , , , , , , , , - Molecular Psychiatry 2021 cited by 62

  18. Drug Repurposing in the Treatment of Traumatic Brain Injury

    Authors: , , , , , - Frontiers in Neuroscience 2021 cited by 33

  19. Neurotrophic and neuroprotective effects of a monomeric GLP-1/GIP/Gcg receptor triagonist in cellular and rodent models of mild traumatic brain injury

    Authors: , , , , , , , , - Experimental Neurology 2019 cited by 27

  20. DPP-4 inhibitors sitagliptin and PF-00734,200 mitigate dopaminergic neurodegeneration, neuroinflammation and behavioral impairment in the rat 6-OHDA model of Parkinson’s disease

    Authors: , , , , , , , , , - GeroScience 2024 cited by 25

  21. Attenuating mitochondrial dysfunction and morphological disruption with PT320 delays dopamine degeneration in MitoPark mice

    Authors: , , , , , , , , , , , , - Journal of Biomedical Science 2024 cited by 18

  22. Transiently lowering tumor necrosis factor-α synthesis ameliorates neuronal cell loss and cognitive impairments induced by minimal traumatic brain injury in mice

    Authors: , , , , , , , - Journal of Neuroinflammation 2015 cited by 131

  23. Sustained Release GLP-1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinson’s Disease

    Authors: , , , , , , , , , , , , , , - ACS Pharmacology & Translational Science 2021 cited by 34

  24. CCL5 is essential for axonogenesis and neuronal restoration after brain injury

    Authors: , , , , , , , , - Journal of Biomedical Science 2024 cited by 24